Health
Cellid, IVI sign research service contract to evaluate immunogenicity of COVID-19 vaccine – News-Medical.Net
Cellid and the International Vaccine Institute have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine “AdCLD-CoV19″….
Cellid and the International Vaccine Institute (IVI) have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine “AdCLD-CoV19”.
Cellid and IVI announced on January 4 that they have signed a research service contract to cooperate in the clinical development of the “AdCLD-CoV19”, a COVID-19 vaccine being developed by Cellid.
Under this contract, IVI will analyze samples from Phase 1/2a clinical trials of Cellid’s COVID-19 vaccine “AdCLD-CoV19” to determine…
-
Business20 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News23 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses
-
Noosa News22 hours agoNick Cave and The Bad Seeds Are Bringing Their ‘Wild God’ Tour to Australia and New Zealand in 2026
-
Business23 hours agoThese small cap ASX shares could rise 10% to 40%